MEP14408A - 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds - Google Patents
4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compoundsInfo
- Publication number
- MEP14408A MEP14408A MEP-144/08A MEP14408A MEP14408A ME P14408 A MEP14408 A ME P14408A ME P14408 A MEP14408 A ME P14408A ME P14408 A MEP14408 A ME P14408A
- Authority
- ME
- Montenegro
- Prior art keywords
- compounds
- production
- pharmaceutical compositions
- compositions containing
- halogenated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 239000003098 androgen Substances 0.000 abstract 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 abstract 1
- 229940124558 contraceptive agent Drugs 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Pronalazsak se odnosi na 17-metilen steroide, postupak za njihovu proizvodnju i farmaceutske sastave koji sadrže ova jedinjenja. Jedinjenja u skladu sa pronalasakom imaju profil dejstva hibridnog tipa u smislu da se ponašaju kao inhibitori 5α-reduktaze i simultano kao gestageni. Oni su zbog toga pogodni za liječenje bolesti koje su rezultat povišenih nivoa androgena u određenim organima i tkivima kod muškaraca i žena. Zajedno sa drugim hormonalnim supstancama, kao što su estrogen, testosteron, ili jaki androgen, jedinjenja u skladu sa pronalaskom su pogodna kao kontraceptivna sredstva za žene i muškarce.The invention relates to 17-methylene steroids, a process for their production and pharmaceutical compositions containing these compounds. The compounds according to the invention have an action profile of the hybrid type in the sense that they act as 5α-reductase inhibitors and simultaneously as progestogens. They are therefore suitable for the treatment of diseases that result from elevated androgen levels in certain organs and tissues in men and women. Together with other hormonal substances, such as estrogen, testosterone, or strong androgen, the compounds according to the invention are suitable as contraceptives for women and men.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10043846A DE10043846A1 (en) | 2000-09-04 | 2000-09-04 | 17-methylene steroids, process for their preparation and pharmaceutical compositions containing them |
| PCT/EP2001/009943 WO2002019971A1 (en) | 2000-09-04 | 2001-08-29 | 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP14408A true MEP14408A (en) | 2010-06-10 |
Family
ID=7655148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-144/08A MEP14408A (en) | 2000-09-04 | 2001-08-29 | 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1423407B1 (en) |
| JP (1) | JP2004513084A (en) |
| KR (1) | KR100530816B1 (en) |
| CN (1) | CN1262560C (en) |
| AT (1) | ATE319733T1 (en) |
| AU (2) | AU1047002A (en) |
| BG (1) | BG107594A (en) |
| BR (1) | BR0113618A (en) |
| CA (1) | CA2421302C (en) |
| DE (2) | DE10043846A1 (en) |
| DK (1) | DK1423407T3 (en) |
| EA (1) | EA006387B1 (en) |
| EE (1) | EE05186B1 (en) |
| ES (1) | ES2260294T3 (en) |
| HK (1) | HK1060135A1 (en) |
| HR (1) | HRP20030256A2 (en) |
| HU (1) | HUP0300936A3 (en) |
| IL (2) | IL154666A0 (en) |
| ME (1) | MEP14408A (en) |
| MX (1) | MXPA03001912A (en) |
| NO (1) | NO325012B1 (en) |
| NZ (1) | NZ524485A (en) |
| PL (1) | PL360669A1 (en) |
| PT (1) | PT1423407E (en) |
| RS (1) | RS50305B (en) |
| SK (1) | SK286757B6 (en) |
| UA (1) | UA74592C2 (en) |
| WO (1) | WO2002019971A1 (en) |
| ZA (1) | ZA200301715B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10141984A1 (en) | 2001-08-28 | 2003-03-20 | Jenapharm Gmbh | New 17-methylene-4-azasteroids |
| US7199115B2 (en) | 2004-04-19 | 2007-04-03 | Schering Ag | 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them |
| AT12800U1 (en) * | 2007-11-05 | 2012-11-15 | Bayer Schering Pharma Ag | A pharmaceutical preparation for use in the oral contraception of lactose intolerant women |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2611773A (en) * | 1951-08-21 | 1952-09-23 | Upjohn Co | Estradiol 17-cyclopenetanepropionate |
| US3146239A (en) * | 1957-09-23 | 1964-08-25 | Syntex Corp | 4-halo-19-nor-progesterone |
| US3232960A (en) * | 1959-10-08 | 1966-02-01 | Upjohn Co | 3-keto-4-fluoro- and 3-keto-4,4-difluorosteroids and process |
| US3661940A (en) * | 1970-04-13 | 1972-05-09 | Sandoz Ag | Derivatives of 21-methyl-19-norpregnanes |
| US4389345A (en) * | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US5994334A (en) * | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| AU2001268661A1 (en) * | 2000-06-27 | 2002-01-08 | Aventis Pharma S.A. | 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase |
-
2000
- 2000-09-04 DE DE10043846A patent/DE10043846A1/en not_active Ceased
-
2001
- 2001-08-29 AT AT01978315T patent/ATE319733T1/en not_active IP Right Cessation
- 2001-08-29 ME MEP-144/08A patent/MEP14408A/en unknown
- 2001-08-29 UA UA2003042852A patent/UA74592C2/en unknown
- 2001-08-29 ES ES01978315T patent/ES2260294T3/en not_active Expired - Lifetime
- 2001-08-29 MX MXPA03001912A patent/MXPA03001912A/en active IP Right Grant
- 2001-08-29 EP EP01978315A patent/EP1423407B1/en not_active Expired - Lifetime
- 2001-08-29 DK DK01978315T patent/DK1423407T3/en active
- 2001-08-29 PT PT01978315T patent/PT1423407E/en unknown
- 2001-08-29 IL IL15466601A patent/IL154666A0/en unknown
- 2001-08-29 JP JP2002524456A patent/JP2004513084A/en active Pending
- 2001-08-29 CA CA002421302A patent/CA2421302C/en not_active Expired - Fee Related
- 2001-08-29 BR BR0113618-6A patent/BR0113618A/en not_active IP Right Cessation
- 2001-08-29 RS YUP-164/03A patent/RS50305B/en unknown
- 2001-08-29 DE DE50109175T patent/DE50109175D1/en not_active Expired - Lifetime
- 2001-08-29 HU HU0300936A patent/HUP0300936A3/en unknown
- 2001-08-29 EE EEP200300087A patent/EE05186B1/en not_active IP Right Cessation
- 2001-08-29 AU AU1047002A patent/AU1047002A/en active Pending
- 2001-08-29 NZ NZ524485A patent/NZ524485A/en unknown
- 2001-08-29 SK SK244-2003A patent/SK286757B6/en not_active IP Right Cessation
- 2001-08-29 PL PL36066901A patent/PL360669A1/en unknown
- 2001-08-29 AU AU2002210470A patent/AU2002210470B2/en not_active Ceased
- 2001-08-29 EA EA200300322A patent/EA006387B1/en not_active IP Right Cessation
- 2001-08-29 CN CNB018151345A patent/CN1262560C/en not_active Expired - Fee Related
- 2001-08-29 WO PCT/EP2001/009943 patent/WO2002019971A1/en active IP Right Grant
- 2001-08-29 KR KR10-2003-7003170A patent/KR100530816B1/en not_active IP Right Cessation
-
2003
- 2003-02-27 IL IL154666A patent/IL154666A/en not_active IP Right Cessation
- 2003-02-27 BG BG107594A patent/BG107594A/en unknown
- 2003-02-28 ZA ZA200301715A patent/ZA200301715B/en unknown
- 2003-03-03 NO NO20030989A patent/NO325012B1/en not_active IP Right Cessation
- 2003-04-04 HR HR20030256A patent/HRP20030256A2/en not_active Application Discontinuation
-
2004
- 2004-04-27 HK HK04102956A patent/HK1060135A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115477T1 (en) | METHODS AND COMPOSITIONS FOR CANCER TREATMENT | |
| BR112012009306A2 (en) | method for myelin regeneration in a patient | |
| NO20020651L (en) | Birch bark treatment and isolation of natural products from birch bark | |
| NO20022292L (en) | New topical estrogen progestogen preparations with systemic effect | |
| AR057060A1 (en) | TANAPROGET COMPOSITIONS CONTAINING ETHYL ESTRADIOL | |
| WO2005077968A3 (en) | 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity | |
| MX2019001323A (en) | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide. | |
| SG158916A1 (en) | Nitrooxy derivatives op glucocorticoids | |
| MX2019001327A (en) | Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride. | |
| DE60330695D1 (en) | ORAL PHARMACEUTICAL COMPOSITION CONTAINING 15-HYDROXYTESTOSTERONE AND ITS DERIVATIVES | |
| Mutiah et al. | Cytotoxic effect of crude extract and fraction from Calotropis gigantea leaves on human colon cancer widr cell lines | |
| NO20053626L (en) | A composition comprising a combination of an aromatase inhibitor, a progestin and an estrogen for use in the treatment of endomeriosis | |
| HUP9903747A2 (en) | New process for the preparation of mometasone furoate | |
| MEP14408A (en) | 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds | |
| BR0008437A (en) | Steroid sulfatase inhibitors and methods for their manufacture and use | |
| RS90504A (en) | C-17 spirolactonization and 6,7 oxidation of steroids | |
| TW200612962A (en) | Estriol and estetrol prodrugs | |
| NO20023276L (en) | Methods of Preparation of Betulinic Acid | |
| ZA201908404B (en) | 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases | |
| AR048829A1 (en) | 17ALFA - FLUOROSTEROIDS WITH INHIBITING ACTIVITY OF 5 ALFA-REDUCTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CANCER DISEASES INFLUENCED BY ANDROGENS. | |
| NO20054636L (en) | Process for the preparation of steroidal carbothioic acid derivatives and intermediates | |
| DK1910398T3 (en) | 17-alpha-substituted derivatives of estradiol with wound healing effect | |
| AR003967A1 (en) | (22R) -N- (1,1,1-TRIFLUORO-2-PHENYLPROP-2-IL) -3-OXO-4-AZA-5ALFA- ANDROST-1-ENO-17BETA-CARBOXAMIDE EPIMERES, A PROCESS FOR YOUR PREPARATION AND A PHARMACEUTICAL COMPOSITION THAT UNDERSTAND THEM. | |
| Ben-juan et al. | Hydrogen peroxide induced apoptosis in SV-40 transformed human salivary gland acinar cells | |
| DE502004004976D1 (en) | USE OF AN OXYTOCIN AND TESTOSTERONE OR ESTRADIOL-CONTAINING MIXTURE FOR TREATING DISORDERS OF PSYCHOSOCIAL EXPERIENCE AND BEHAVIOR |